HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dean Rudge

Senior Reporter

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Fresenius Kabi Partners On Propofol Supply For COVID-19

Fresenius Kabi’s Diprivan sedative was added to the US FDA’s drug shortage list in April as the COVID-19 pandemic peaked. A long-term committed purchasing agreement signed between the German firm and Premier Inc. will guarantee adequate supply and manage any future surges, the US hospitals group believes.

Deals Coronavirus COVID-19

Amneal Approval Leads Lannett To Job Losses

Around 80 more jobs are to go at Lannett, as the company reels from rival Amneal bagging US Food and Drug Administration approval for the company’s top seller.

Strategy Generic Drugs

Saudi Insurer Ponders Framework For Saving Billions

Bupa Arabia for Cooperative Insurance believes savings of up to 40% per year could be achieved if Saudi Arabia opted for legislation to drive uptake of generic medicines.

Policy & Regulation Saudi Arabia

Centrient Hits Milestone On Antimicrobial Resistance

Centrient has declared itself one of the first companies to announce progress in achieving Predicted No-Effect Concentration discharge targets for the largest part of its antibiotics – the firm’s semi-synthetic penicillin active pharmaceutical ingredients portfolio. In addition, 97% of Centrient’s SSP finished-dose formulation products are also PNEC compliant, according to the firm.

Strategy International

Mylan And Upjohn Unveil Viatris Logo And Branding

Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”

Strategy Companies

Amgen Settles On Bevacizumab And Trastuzumab

Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.

Intellectual Property Legal Issues
See All